Quarterly report · Q2
2370.TEDINET S100QQH6
Period2022-10-01 → 2023-03-31
Filed2023-05-12
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥349m | 2022-10-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥634m | 2021-10-01 → 2022-09-30 | Standalone | Net sales (5-year summary) |
| Revenue | ¥318m | 2021-10-01 → 2022-03-31 | Standalone | Net sales |
| Operating income | −¥672m | 2022-10-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | −¥678m | 2021-10-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | −¥670m | 2022-10-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2021-10-01 → 2022-09-30 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥676m | 2021-10-01 → 2022-03-31 | Standalone | Ordinary income |
| Profit before tax | −¥674m | 2022-10-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥676m | 2021-10-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | −¥677m | 2022-10-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | −¥1.3bn | 2021-10-01 → 2022-09-30 | Standalone | Net income loss (5-year summary) |
| Net income | −¥679m | 2021-10-01 → 2022-03-31 | Standalone | Profit loss |
| Total assets | ¥5.4bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥6.1bn | at 2022-09-30 | Standalone | Assets |
| Total assets | ¥6.3bn | at 2022-03-31 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥529m | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥566m | at 2022-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥4.9bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥5.5bn | at 2022-09-30 | Standalone | Net assets |
| Net assets / equity | ¥5.6bn | at 2022-03-31 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.0bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.5bn | at 2022-09-30 | Standalone | Cash and deposits |
| Cash & equivalents | ¥4.0bn | at 2023-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2022-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.3bn | at 2022-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.1bn | at 2021-09-30d | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥564m | 2022-10-01 → 2023-03-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2021-10-01 → 2022-09-30 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥612m | 2021-10-01 → 2022-03-31 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | −¥35m | 2022-10-01 → 2023-03-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥20m | 2021-10-01 → 2022-09-30 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥23m | 2021-10-01 → 2022-03-31 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | ¥133m | 2022-10-01 → 2023-03-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.6bn | 2021-10-01 → 2022-09-30 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥885m | 2021-10-01 → 2022-03-31 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-3.19 | 2022-10-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.66 | 2023-01-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.33 | 2021-10-01 → 2022-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.63 | 2021-10-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.75 | 2022-01-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 89.6% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.7% | at 2022-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 213,465,757 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 211,730,423 | at 2022-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 197,000,423 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2022-10-01 → 2023-03-31 | −¥313m |
| jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥276,000 |
| jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥276,000 |
| jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segment | segment profit | 2022-10-01 → 2023-03-31 | −¥225m |
| jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥349m |
| jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥349m |
| jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segment | segment profit | 2022-10-01 → 2023-03-31 | −¥133m |
| —segment total | revenue | 2022-10-01 → 2023-03-31 | ¥349m |
| —segment total | revenue external | 2022-10-01 → 2023-03-31 | ¥349m |
| —segment total | segment profit | 2022-10-01 → 2023-03-31 | −¥358m |
| Reconciling Itemsreconciling | segment profit | 2021-10-01 → 2022-03-31 | −¥265m |
| jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥69,000 |
| jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥69,000 |
| jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segment | segment profit | 2021-10-01 → 2022-03-31 | −¥308m |
| jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥318m |
| jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥318m |
| jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segment | segment profit | 2021-10-01 → 2022-03-31 | −¥105m |
| —segment total | revenue | 2021-10-01 → 2022-03-31 | ¥318m |
| —segment total | revenue external | 2021-10-01 → 2022-03-31 | ¥318m |
| —segment total | segment profit | 2021-10-01 → 2022-03-31 | −¥413m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 461
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating income | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | -358414000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | -313410000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember | -671824000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-05-12 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第28期第２四半期（自 2023年１月１日 至 2023年３月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社メディネット | |
| Company name in english cover page | FilingDateInstant | MEDINET Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 久布白 兼直 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都品川区勝島一丁目５番21号（同所は登記上の本店所在地であり、実際の業務は「最寄りの連絡場所」で行っております。） | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)該当事項はありません。 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)該当事項はありません。 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都大田区平和島六丁目１番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)（０３）６６３１－１２０１（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役経営管理部長 落合 雅三 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05351 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 23700 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社メディネット | |
| Filer name in english | FilingDateInstant | MEDINET Co., Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | false | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2022-10-01 | |
| Current period end date | FilingDateInstant | 2023-03-31 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2023-09-30 | |
| Previous fiscal year start date | FilingDateInstant | 2021-10-01 | |
| Comparative period end date | FilingDateInstant | 2022-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2022-09-30 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Material matters relating to going concern etc business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |